Efficacy of Calprotectin as A Marker For the Pathogenicity of Blastocystis Infection
NCT ID: NCT05724368
Last Updated: 2023-02-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
150 participants
OBSERVATIONAL
2023-03-31
2025-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In developed countries, the prevalence ranges from 0.5% to 23.1%. The high prevalence noted in developing countries is related to poor hygiene and lack of safe water and food .
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Novel Listeria Vectors Secreting Gut Flora-Altering Agents to Prevent Colon Cancer and Treat Colitis
NCT03014284
Evaluation of the Consumption of a Probiotic on the Load of S. Agalactiae.
NCT04165551
Safety and Tolerability of Bacillus Subtilis MB40 in Healthy Adult Volunteers
NCT04655352
Probiotics Capsule as Supplemental Therapy for Group B Streptococci Infection and Vaginitis During Pregnancy
NCT01779193
Lactobacillus Reuteri for Treatment of Uncomplicated UTI in Pregnant Women
NCT03362697
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In developed countries, the prevalence ranges from 0.5% to 23.1%. The high prevalence noted in developing countries is related to poor hygiene and lack of safe water and food. The pathogenicity of Blastocystis is controversial because most patients carrying this parasite are asymptomatic. Several studies have considered Blastocystis sp. as a commensal micro-organism, while other results have showed the pathogenicity of the parasite.
Calprotectin (CP), a calcium-binding protein, comprises 60% of cytosolic protein found in neutrophils. Fecal calprotectin (F-CP) concentration is an indicator of neutrophil migration into the intestinal lumen and is associated with intestinal inflammation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Patients with gastrointestinal symptoms and positive only for Blastocystis.
Fecal Calprotectin ELISA kit
* Routine stool examination will be done in addition to certain concentration, staining and culture techniques.
* Fecal calprotectin will be evaluated using ELISA kits according to the manufacturer's instructions.
Group 2
Patients with gastrointestinal symptoms and Blastocystis free.
Fecal Calprotectin ELISA kit
* Routine stool examination will be done in addition to certain concentration, staining and culture techniques.
* Fecal calprotectin will be evaluated using ELISA kits according to the manufacturer's instructions.
Group 3
Healthy volunteers with neither gastrointestinal symptoms nor parasitological infections.
Fecal Calprotectin ELISA kit
* Routine stool examination will be done in addition to certain concentration, staining and culture techniques.
* Fecal calprotectin will be evaluated using ELISA kits according to the manufacturer's instructions.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fecal Calprotectin ELISA kit
* Routine stool examination will be done in addition to certain concentration, staining and culture techniques.
* Fecal calprotectin will be evaluated using ELISA kits according to the manufacturer's instructions.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
6 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shimaa Refaey Mohamed Abd-Elal
Assistant lecturer of medical parasitology at the Faculty of Medicine
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Shimaa Refaey Mohamed AbdElal, Assistant Lecturer
Role: CONTACT
Khoulood Zakaria Hashem Abd-Elhafez, Assistant Lecturer
Role: CONTACT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Soh-Med-23-01-24
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.